Slingshot members are tracking this event:
AbbVie Receives Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain
- Marks the first FDA Rare Pediatric Designation for an AbbVie investigational medicine
- In 2014, the FDA and European Medicines Agency granted ABT-414 Orphan Drug Designation for the treatment of glioblastoma and glioma in adults, respectively
Slingshot Insights Explained
Jul 11, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Abt-414, Diffuse Intrinsic Pontine Glioma, Pediatric Brain Tumor